Why is Titan Biotech falling/rising?

As of 18-Jul, Titan Biotech Ltd's stock price is currently at 458.00, reflecting an increase of 3.8 (0.84%). The stock has outperformed its sector today by 1.87%, although it has shown a decline of 0.97% over the past week. In terms of moving averages, the stock is higher than the 20-day, 50-day, and 100-day averages but lower than the 5-day and 200-day averages. Despite a high return on equity (ROE) of 25.08% and a low debt-to-equity ratio, the company has faced challenges, including negative results for the last three consecutive quarters and a significant decline in profit before tax (PBT) and profit after tax (PAT). Over the past year, the stock has underperformed the market, with a return of -21.82% compared to the BSE500's -0.36%.
In the broader market context, while Titan Biotech has shown a positive return of 7.59% over the past month, its year-to-date performance remains poor at -37.50%, indicating long-term growth concerns. The stock's recent price increase may be attributed to short-term trading dynamics rather than a fundamental recovery, as evidenced by falling investor participation and a significant drop in delivery volume. The company's high valuation relative to its peers, combined with a lack of consistent profitability growth, suggests that the stock may still face headwinds despite today's positive movement.